Medicover sp. z o.o. Medicover Opieka Szpitalna Centrum Leczenia Chorób Serca i Naczyń Medicover
- Address
- lock Available on a paid plan
Medicover Center for Heart and Vascular Disease Treatment
Medicover Opieka Szpitalna Centrum Leczenia Chorób Serca i Naczyń is a specialized cardiovascular care center focused on advancing treatment strategies for patients undergoing complex cardiac procedures. The center participates in cutting-edge clinical research aimed at preventing serious complications associated with cardiac surgery, particularly in vulnerable patient populations.
- Prevention of cardiac surgery-associated acute kidney injury in chronic kidney disease patients
- Cardiopulmonary bypass surgical procedures and complication management
- Major adverse kidney events prevention following cardiovascular surgery
Through participation in Phase 3 clinical trials, the center evaluates innovative complement inhibitor therapies designed to protect patients with chronic kidney disease from developing acute kidney injury following cardiac surgery. This research focus demonstrates the center's commitment to improving outcomes for high-risk cardiac patients and reducing the burden of post-operative complications that can significantly impact long-term kidney function and patient survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicover sp. z o.o. Medicover Opieka Szpitalna Centrum Leczenia Chorób Serca i Naczyń Medicover
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study | Alexion Pharmaceuticals Inc. | Phase III | Not Recruiting | Jun 2023 | Apr 2026 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ravulizumab | 1 | Unknown | 2023-06-16 | 2023-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.